Vanguard Portfolio Management
ANAB icon

Vanguard Portfolio Management’s AnaptysBio ANAB Stock Holding History

Vanguard Portfolio Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.6M Buy
527,858
+7,988
+2% +$484K ﹤0.01% 1810
2026
Q1 		$28.8M Buy
+519,870
New +$28M ﹤0.01% 1805

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vanguard Portfolio Management's ANAB Position: Q2 2026 in Review

Vanguard Portfolio Management increased its AnaptysBio (ANAB) stake by 1.5% in Q2 2026, buying an estimated $484K and bringing the position to 527,858 shares worth $35.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1810.

Vanguard Portfolio Management first reported a position in ANAB in Q1 2026 and has held it in 2 quarters since. 211 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Vanguard Portfolio Management held 527,858 shares of AnaptysBio worth $35.6M as of Q2 2026.
  • Vanguard Portfolio Management bought 7,988 AnaptysBio shares in Q2 2026, an estimated $484K.
  • AnaptysBio made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #1810 holding.
  • Vanguard Portfolio Management first reported a position in AnaptysBio in Q1 2026 and has held it in 2 quarters since.
  • 211 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.